Please login to the form below

Not currently logged in

Bayer files regorafenib for GIST in US

Follows priority review for drug in metastatic colorectal cancer

Bayer building

Bayer has filed for approval of its investigational cancer drug candidate regorafenib as a treatment for gastrointestinal stromal tumours (GIST) in the US.

The application comes a few weeks after the pharma company filed its first marketing applications for the oral multi-kinase inhibitor for metastatic colorectal cancer in the US and Europe, with the FDA granting it a priority review.

The drug is one of four in Bayer's late-stage pipeline that are tipped to have blockbuster sales potential, and analysts have suggested that GIST alone could be a market worth $500m for the drug.

The latest filing with the FDA is seeking approval for regorafenib in metastatic GIST, or cases which are not treatable with surgery, in patients whose disease has progress despite treatment with other kinase inhibitors.

GIST - a rare type of sarcoma which occurs most often in the stomach wall - is typically treated with Novartis' Glivec/Gleevec (imatinib) in the first instance and with Pfizer's Sutent (sunitinib) as a second-line option.

Novartis recently stopped a phase III trial of another candidate GIST treatment called Tasigna (nilotinib) after data indicated that the drug was unlikely to demonstrate superiority in progression-free survival over Glivec.

Bayer filed for approval of regorafenib in GIST on the back of the 199-patient GRID study, which found that regorafenib significantly improved progression-free survival (PFS) compared to placebo. The median PFS was 4.8 months in the regorafenib arm versus 0.9 months in the placebo arm.

"The submission of regorafenib for the treatment of GIST brings us one step closer to meeting a significant medical need for patients with this aggressive disease," said Bayer's head of global development Kemal Malik.

Regorafenib was at the heart of a dispute between Bayer and partner Onyx Pharmaceuticals, which filed a lawsuit against the German drugmaker in 2009 claiming rights to the drug under the terms of a collaboration between the firms which led to the development of kidney and liver cancer drug Nexavar (sorafenib).

The suit was settled last year after the two companies agreed that regorafenib is a Bayer compound but Onyx would receive a 20 per cent royalty on sales.

31st August 2012


Featured jobs

Subscribe to our email news alerts


Add my company

Consult is a bespoke data collection service designed to support marketing research clients in meeting those changing, increasingly focused research...

Latest intelligence

White paper download: Creating experiences to improve patient outcomes
Download our white paper "Creating experiences to improve patient outcomes" to learn the steps to building an effective customer experience strategy....
Organisational Memory
In a knowledge-based industry with high labour mobility, retaining that knowledge within an organisation during a drug’s lifecycle can be tricky. If we undervalue the knowledge, experience and marketing understanding...
Thoughts on the intersection between technology and psychology
Paul Mannu - Master Practitioner, Behavioural Insights at Cello Health Insight gives us his succinct thoughts on the intersection between technology and psychology...